Klinotab (Minocycline)

Minocycline inhibits bacterial protein synthesis by binding to the 30S ribosomal subunit. This prevents the addition of amino‑acyl tRNA to the growing peptide chain, halting bacterial growth and allowing the immune system to clear the infection.

The dosage of Klinotab is individualized by the prescribing clinician based on the specific infection, its severity, patient weight, renal and hepatic function, and any concomitant medications. No fixed regimen is provided here.

Klinotab is classified as Pregnancy Category D, indicating evidence of fetal risk. It should only be used during pregnancy if the potential benefit justifies the risk. Minocycline is excreted in breast milk and is generally not recommended while breastfeeding.

To order Klinotab, submit an enquiry on the product page at gnhindia.com, specifying the required quantity. GNH India works with hospitals, pharmacies and procurement teams worldwide, verifies trade or institutional credentials, and then provides pricing, availability, shipping details (including any temperature‑controlled requirements) and necessary import documentation.

Both minocycline (Klinotab) and doxycycline belong to the tetracycline class and share similar spectrums of activity. Minocycline generally has higher lipid solubility, offering better tissue penetration and a longer half‑life, which may allow once‑daily dosing. Doxycycline is often preferred for its lower risk of vestibular side effects, while minocycline may be chosen for severe acne or infections requiring deeper tissue levels.

Klinotab tablets should be stored at ambient temperature, preferably below 25 °C. Keep them in the original container, protect from moisture and direct sunlight, and ensure the packaging remains tightly closed until use.

Klinotab is taken orally with a full glass of water. It may be taken with or without food, but if gastrointestinal upset occurs, it can be administered with meals. Patients should follow the prescriber’s instructions regarding timing relative to antacids or supplements.

Serious adverse events include Stevens‑Johnson syndrome or toxic epidermal necrolysis, drug‑induced hepatitis, severe vestibular toxicity (vertigo, ataxia), hypersensitivity reactions such as anaphylaxis, and pseudotumor cerebri (intracranial hypertension). Immediate medical attention is required if any of these symptoms develop.

Klinotab should be avoided in patients with known hypersensitivity to minocycline or other tetracyclines, children younger than eight years, pregnant women unless absolutely necessary, and individuals with severe hepatic impairment. Caution is also advised for patients with renal dysfunction, a history of intracranial hypertension, or those taking interacting medications listed under major interactions.